Key Outcomes: Ophthalmology expansion: Eylea 8 mg gained EU approval for macular edema following RVO, demonstrating comparable efficacy to 2 mg with longer dosing intervals, reinforcing the Bayer–Regeneron retina franchise Oncology advancements: Multiple KRAS-targeted programs progressed, with D3 Bio securing dual FDA INDs (G12D, G12C), and first patient dosing achieved by PAQ Therapeutics and Argo […]

Key Outcomes: Daiichi initiated P3 of Datopotamab deruxtecan (Datroway) for NSCLC, Pfizer’s P3 BREAKWATER study showed promising combinations in BRAF V600E mCRC, reinforcing global ADC and targeted therapy focus Biopharma deal-making remained strong across oncology and immunology, with multiple high-value licensing and collaboration agreements Pipeline momentum was robust in neurology and rare diseases, as Eisai/Biogen […]